12 Best Immunotherapy Stocks to Buy According to Hedge Funds

Page 7 of 11

5. Amgen Inc. (NASDAQ:AMGN)

Number of Hedge Fund Holders: 62

Amgen Inc. (NASDAQ:AMGN) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Amgen Inc. (NASDAQ:AMGN) was downgraded to Hold from Buy by Freedom Capital, with the firm adjusting the price target on the stock to $375 from $360. It told investors in a research note that while it views the company’s fiscal Q4 report as “strong”, the shares are at fair value and loss of exclusivity headwinds remain for Amgen Inc. (NASDAQ:AMGN).

The rating update came the same day Amgen Inc. (NASDAQ:AMGN) announced that the European Commission’s approval of UPLIZNA® as an add-on treatment to standard therapy for adults living with generalized myasthenia gravis who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive. Management stated that the approval provides patients with a new and targeted treatment option, and holds the potential for long-term disease control through twice-yearly maintenance dosing, following two initial loading doses.

Amgen Inc. (NASDAQ:AMGN) also reported its fiscal Q4 and full-year 2025 results on February 3, announcing strong performance in 2025 with double-digit growth in revenues and EPS. Total revenues for fiscal Q4 rose 9% to $9.9 billion compared to the prior year period, with product sales growing 7%, driven by 10% volume growth. Total revenues for the full year reached $36.8 billion, up 10% compared to the same quarter last year.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers, develops, manufactures, and markets human therapeutics. It delivers new therapies for patients with complex cancers, especially in areas with significant unmet needs.

Page 7 of 11